Molbio Diagnostics Aims for Growth with ₹940 Crore IPO

Molbio Diagnostics, a key player in the molecular diagnostics sector, is gearing up for an initial public offering (IPO) aimed at raising ₹940 crore. The company plans to use ₹200 crore from the fresh issue to bolster its capital expenditures, while the remaining ₹740 crore will be raised through an offer for sale, reducing the promoter's stake from 46.6% to 43%.

Expansion and Revenue Growth

Founded in 2000, Molbio has established itself in the diagnostics industry with six manufacturing sites across India, serving over 90 countries. The company’s revenue has seen significant growth, largely driven by its tuberculosis diagnostic test kits. Key clients, including government health programs and international aid agencies, contribute to more than 80% of its revenue.

Molbio's flagship product, the 'Truenat' platform, offers portable diagnostics for resource-limited settings, delivering accurate results within an hour. This system supports molecular testing for over 30 diseases with 43 diagnostic assays. The company also offers solutions in radiology, digital pathology, and breast health screening through its subsidiaries and partnerships.

Financial Performance

From FY24 to FY26, Molbio's revenue from operations increased by 31.5% annually, totaling ₹1,445.7 crore. Net profit rose by 40.2% annually to ₹164.1 crore. The operating profit before interest, tax, depreciation, and amortization (EBITDA) grew by 33.2%, reaching ₹328.2 crore, with an EBITDA margin improvement to 22.6% in FY26 from 22% in FY24.

In FY26 alone, the company reported a 41.7% year-on-year revenue growth, a 27.9% increase in EBITDA, and an 18.4% rise in net profit. These figures underscore Molbio's robust financial health and growth trajectory.

Market Position and Valuation

Molbio's IPO valuation demands a price-earnings (P/E) multiple of up to 57, positioning it among other prominent healthcare diagnostics and medical device companies like Poly Medicure and Dr. Lal PathLabs, which trade at P/E multiples between 54 and 81.

While Molbio does not have a directly comparable listed peer in India, its performance and strategic initiatives make it an attractive option for high-risk investors looking for long-term growth potential. The company's focus on expanding its diagnostic solutions and enhancing its manufacturing capabilities could further solidify its market position.